Plain-English translation of NCT06363734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether osimertinib and dalpiciclib work better together than either medication alone for people with advanced lung cancer that has stopped responding to previous treatments. Both medications target specific parts of cancer cells that have become resistant to standard therapy. The goal is to see if combining them can slow or stop cancer growth.
When people with this type of lung cancer take standard treatments for a while, the cancer can develop resistance and start growing again. Doctors believe combining this medication with another drug that targets a different pathway might overcome that resistance and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would take osimertinib (80 mg) and dalpiciclib (125 mg) by mouth once daily for 21 days, then have 7 days off, repeating this 28-day cycle for as long as the treatment is working and side effects remain manageable. You would have regular visits to your study doctor for blood tests, imaging scans, and check-ins to monitor how you're responding and manage any side effects. The treatment continues until your cancer progresses, side effects become too difficult to manage, or you and your doctor decide to stop.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China